VIROGENICS, INC.

Company Information
Address PO BOX 2702
DEL MAR, CA, 92014-


Information

DUNS: 146101196

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    Amount: $1,499,999.00

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the grea ...

    STTRPhase II2016Department of Health and Human Services National Institutes of Health
  2. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    Amount: $599,936.00

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most p ...

    STTRPhase I2013Department of Health and Human Services
  3. siRNA Modulation of the Immune Response

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): A major goal expressed by NIAID and other agencies charged with development of the U.S. biodefense research strategy is a broad spectrum activity that mitigates c ...

    SBIRPhase I2013Department of Health and Human Services
  4. FIV Vectors for the Treatment of Hemophilia A

    Amount: $2,309,520.00

    DESCRIPTION (provided by applicant): Although several labs including ours have demonstrated the feasibility of gene therapy for hemophilia A in animal models, long-term expression of the transgene at ...

    SBIRPhase II2010Department of Health and Human Services
  5. A Novel Immune Modulator/ Adjuvant for HIV Vaccines

    Amount: $599,314.00

    DESCRIPTION (provided by applicant): During the past two decades of HIV vaccine development, a wide variety of AIDS vaccine strategies have been explored. Among the many tested, DNA and viral vector-b ...

    SBIRPhase I2008Department of Health and Human Services
  6. Hemophilia A: Intrathymic Delivery for Tolerance and Longterm Expression of FVIII

    Amount: $149,881.00

    DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous human factor VIII (hFVIII) protein infusions, either prophylactically or during bleedin ...

    SBIRPhase I2007Department of Health and Human Services
  7. Non-Integrating FIV Vectors for HIV Vaccines

    Amount: $600,002.00

    DESCRIPTION (provided by applicant): The diagnosis of 15,000 new cases of HIV infections every day demonstrates the pressing need for a prophylactic HIV vaccine to prevent further spread of the pandem ...

    SBIRPhase I2006Department of Health and Human Services
  8. FIV Vectors for the Treatment of Hemophilia A

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous FVIII protein infusions, either prophylacticly or during bleeding episodes. Prophylacti ...

    SBIRPhase I2005Department of Health and Human Services
  9. Lentiviral Vector Gene Therapy for CD45 Deliver

    Amount: $748,800.00

    DESCRIPTION (provided by the applicant): The overall goal of this project is to address the need for an effective therapy for patients with severe combined immunodeficiency due to loss of CD45 functio ...

    SBIRPhase I2003Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government